论文部分内容阅读
目的观察重组人粒细胞刺激因子(rhG-CSF)的临床疗效和不良反应。方法入选对象均为细胞或组织学诊断的恶性肿瘤患者,全组60例,均行自身对照法,以第1次化疗周期为对照周期,此后采用口服鲨肝醇、利血生使白细胞恢复正常后开始第2周期(治疗周期)化疗,于治疗周期化疗后加用rhG-CSF,化疗开始隔日查血常规1次,观察白细胞及中性粒细胞的变化。结果治疗周期白细胞总数及中性粒细胞的最低值[(3.0±2.0)×109/L,(2.5±0.8)×109/L]均高于对照周期[(2.2±0.8)×109/L,(1.3±0.7)×109/L],最低值的持续时间也少于对照周期,骨痛、肌痛以及乏力发生率为10%和7%,偶有低热。结论rhG-CSF对化疗引起的白细胞和中性粒细胞减少具有预防和治疗作用,不良反应轻,安全可靠。
Objective To observe the clinical efficacy and adverse reactions of recombinant human granulocyte-stimulating factor (rhG-CSF). Methods The selected patients were all patients with malignant tumors diagnosed by cell or histology. All 60 patients underwent self-control. The first chemotherapy cycle was used as the control period. After that, oral batyl alcohol and reserpine were used to restore normal white blood cells After the start of the second cycle (treatment cycle) of chemotherapy, chemotherapy cycles after the addition of rhG-CSF, chemotherapy began the next day routine blood tests to observe the changes in white blood cells and neutrophils. Results The total number of leukocytes and neutrophils in the treatment group were significantly higher than those in the control group [(3.0 ± 2.0) × 109 / L, (2.5 ± 0.8) × 109 / L, (1.3 ± 0.7) × 109 / L]. The duration of the lowest value was also less than that of the control period. The incidence of bone pain, myalgia and fatigue was 10% and 7%, with occasional fever. Conclusions rhG-CSF can prevent and treat leukopenia and neutropenia induced by chemotherapy. The adverse reaction is light and safe.